Recursion Pharmaceuticals (RXRX) added ~11% in the morning trading on Wednesday after J.P. Morgan upgraded the AI-driven biotech to Overweight from Neutral, citing a blockbuster sales potential for ...

A new research paper reframes the simulation hypothesis, asking whether reality could be simulated and what science can test.

Leveraging modular gene editors and new regulatory pathways, Aurora will develop and commercialize therapies that can be rapidly tailored to many rare variants -- Founded by CRISPR pioneers Jennifer ...

Biopharma may see a happier year ahead in 2026 than in recent years, according to analysts at William Blair. For one thing, the industry’s top stocks have recovered from lows that stretched into last ...

Since the 2000s, Google Search—and later YouTube and Discover—served as the primary discovery and monetization engines for digital publishing. This relationship was symbiotic, if lopsided. Two decades ...

Former Google CEO Eric Schmidt believes AI's rapid advancement, already handling 10-20% of programming tasks, signals the end ...

Abstract: A new controlled switching method for purely series compensated transmission lines is proposed here. The main idea is based on the estimation of trapped charges using a recursive digital ...

Abstract: Abstract Syntax Tree (AST) and Control Flow Graph (CFG) are program code representations widely used for static analysis. One of the uses of static analysis is for automated grading ...

Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger. In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes ...

In one of the biggest M&A deals involving artificial intelligence-focused drug developers to date, Recursion Pharma has agreed to join with Exscientia in an all-stock transaction valued at $688 ...

On a Tuesday at the end of last semester, I asked my first-year writing class how they were using AI in their courses. One of ...